Teva presents latest data on AJOVY® ▼ (fremanezumab) at EHF Congress
AMSTERDAM, NETHERLANDS – Teva Pharmaceutical Europe B.V. has presented results from a pooled analysis of three randomized, double-blind, placebo-controlled Phase 3 studies assessing AJOVY® ▼ (fremanezumab), indicated for the preventative treatment of migraine in adults, which demonstrate clinically significant reductions in headache and migraine-related disability in the majority of patients studied. The findings, presented at…